Leukemia

My wife and I are always amazed at the fond memories and warm feelings that rise up when we return to Nashville.

ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). This is the first approval the agency received for immunophenotyping on a flow cytometer.

Rituxan Hycela (rituximab) was granted approval by the Food and Drug Administration (FDA) for adult patients with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL) and previously untreated and previously treated chronic lymphocytic leukemia (CLL).

Imbruvica (ibrutinib) continues to demonstrate benefit in patients with chronic lymphocytic leukemia (CLL) who had at least one prior therapy, according to a four-year follow-up of the RESONATE study, which compared the BTK inhibitor to Arzerra (ofatumumab).

VYXEOS (CPX-351), a novel injection, was granted a new drug application (NDA) by the Food and Drug Administration (FDA), granting the drug a priority review for the treatment of acute myeloid leukemia (AML), according to Jazz Pharmaceuticals, the producer of the drug.

Experts discuss how to have the best chances for a complete response for patients with chronic lymphocytic leukemia (CLL) who developed Hodgkin lymphoma (HL).

The Food and Drug Administration has approved Rydapt (midostaurin) for acute myeloid leukemia (AML).

"Neither feels guilty about surviving — although both have had plenty of reminders that they’re dealing with cancer — and both have found ways to continue enjoying life."

All members of the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted to approve Rituxan for the treatment of some blood cancers.

Jim Kochenderfer, M.D., lends insight to the future of CAR T-cell therapy for hematologic malignancies.

Just one person can make a difference for patients with blood cancer.

Hope is growing for patients who are living with CML.

In a recent study, Blincyto (blinatumomab) had longer survival rates than standard chemotherapy for certain patients with ALL.

As Ed completes his final chemo cycle, he loses a friend.

More people with AML who were treated with Vyxeos were moved to transplant than those treated with a standard chemotherapy regimen, according to recent findings.

Inotuzumab ozogamicin was granted a priority review designation for patients with relapsed or refractory ALL.

A supplemental biologics license application was filed for Blincyto to be approved for certain patients with ALL.

There is a need for more targeted clinical trials for patients with ALL, since many of them have Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia.

Group exercise programs are beneficial to survivors of cancer, and can offer motivation from peers to continue living a healthy lifestyle.

Imbruvica (ibrutinib) improved survival for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL), according to study results that were recently presented.

Many patients with cancer do not qualify for clinical trials because of comorbidities or other health problems. However, a recent study found that many of these patients can actually benefit from trials.

Several trials testing vadastuximab talirine for use in patients with AML were recently halted, according to the drug's manufacturer.

Recent studies found that for certain patients with CML, it is possible to safely reduce or stop TKI treatment.

CTL019, a CAR T-cell therapy, had a high response rate for young patients with relapsed/refractory ALL in a recent phase 2 study.

Having multiple options for frontline treatment of CLL may be better than deciding on one standard, an expert says.

The treatment landscape for chronic lymphocytic leukemia (CLL) is going to drastically change over the next decade or so, says Jose Leis, M.D.

Through music, Christian Hoff shares his message of hope for patients and survivors of cancer.

Midostaurin was granted a priority review for a new drug application by the FDA to treat a subset of patients with acute myeloid leukemia.

The NCCN updated their guidelines on treatment for myeloproliferative neoplasms (MPNs), outlining diagnosis, treatment and care strategies.